Acquired Company

Datuk Dr. Doris Wong Sing Ee acquired Cyclacel Pharmaceuticals, Inc. on 2/26/2025 through purchase of Series C and Series D Convertible Preferred Stock, giving her 70% of the outstanding shares for $6,300,000 in cash and other consideration, and she was appointed CEO; the closing date was February 26, 2025.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia. Show more

Level 10, Kuala Lumpur, 592000, Malaysia

https://www.cyclacel.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

14.25M

52 Wk Range

$3.08 - $597.60

Previous Close

$6.36

Open

$6.36

Volume

N/A

Day Range

$6.36 - $6.36

Enterprise Value

-60.46K

Cash

4.275M

Avg Qtr Burn

-2.182M

Insider Ownership

79.47%

Institutional Own.

0.80%

Qtr Updated

06/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Oral Fadraciclib (CDK2 & CDK9) Details Solid tumor/s, Lymphoma, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Oral Plogosertib Details Lymphoma, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.